Jessica Perl - Emergent Biosolutions Corporate Counsel

Emergent Biosolutions Management Efficiency

The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.59 in 2024. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2024.

Similar Executives

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people. Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Gaithersburg, MD, United States, 20879 and employs 1,600 people. Emergent Biosolutions is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Emergent Biosolutions Leadership Team

Emergent Stock Performance Indicators

Additional Tools for Emergent Stock Analysis